<qa>  Phase III was randomized, double-blind, double-dummy, active controlled,Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care SL BPN in initiation and maintenance treatment with BPN. 